{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:51Z","timestamp":1791920871091,"version":"4.3.4"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.bcp.2011.03.027","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T19:28:40Z","timestamp":1302895720000},"page":"99-109","source":"Crossref","is-referenced-by-count":120,"title":["The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond"],"prefix":"10.1016","volume":"82","author":[{"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2011.03.027_bib0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/323464a0","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"De Clercq","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2011.03.027_bib0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nature04295","article-title":"Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection","volume":"439","author":"Stittelaar","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2011.03.027_bib0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0166-3542(87)80004-9","article-title":"Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines","volume":"8","author":"De Clercq","year":"1987","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bcp.2011.03.027_bib0020","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2011.03.027_bib0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.200.4341.563","article-title":"(S)-9-(2,3-Dihydroxypropyl)adenine: an aliphatic nucleoside ana log with broad spec trum antiviral activity","volume":"200","author":"De Clercq","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.bcp.2011.03.027_bib0030","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1128\/AAC.34.7.1326","article-title":"Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro","volume":"34","author":"Yokota","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0035","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/AAC.35.2.394","article-title":"Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis","volume":"35","author":"Yokota","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0040","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1021\/jm050473m","article-title":"Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses","volume":"49","author":"Beadle","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2011.03.027_bib0045","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1128\/AAC.00184-07","article-title":"Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxy-ethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0050","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2011.03.027_bib0055","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bcp.2011.03.027_bib0060","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0065","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1128\/AAC.01223-05","article-title":"Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro","volume":"50","author":"Hostetler","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0070","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1128\/AAC.01546-08","article-title":"The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons","volume":"53","author":"Wyles","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0075","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1128\/AAC.32.12.1839","article-title":"(S)-1-(3-hydroxy-2-Phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication","volume":"32","author":"Snoeck","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0080","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/med.20173","article-title":"Yet another ten stories on antiviral drug discovery (part D): paradigms, paradoxes, and paraductions","volume":"30","author":"De Clercq","year":"2010","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bcp.2011.03.027_bib0085","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/med.20179","article-title":"The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures","volume":"31","author":"De Clercq","year":"2011","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bcp.2011.03.027_bib0090","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jmv.1890450221","article-title":"Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine","volume":"45","author":"Van Cutsem","year":"1995","journal-title":"J Med Virol"},{"key":"10.1016\/j.bcp.2011.03.027_bib0095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1096-9071(199803)54:3<219::AID-JMV13>3.0.CO;2-C","article-title":"Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine]","volume":"54","author":"Snoeck","year":"1998","journal-title":"J Med Virol"},{"key":"10.1016\/j.bcp.2011.03.027_bib0100","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/archotol.125.10.1143","article-title":"Intralesional cidofovir for recurrent respiratory papillomatosis in children","volume":"125","author":"Pransky","year":"1999","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.bcp.2011.03.027_bib0105","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1067\/mjd.2000.100534","article-title":"Large plantar wart caused by human papillomavirus-66 and resolution by topical cidofovir therapy","volume":"43","author":"Davis","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bcp.2011.03.027_bib0110","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/archderm.1997.03890440061010","article-title":"Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir","volume":"133","author":"Meadows","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bcp.2011.03.027_bib0115","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/jmv.1084","article-title":"A case of human orf in an immunocompromised patient treated successfully with cidofovir cream","volume":"64","author":"Geerinck","year":"2001","journal-title":"J Med Virol"},{"key":"10.1016\/j.bcp.2011.03.027_bib0120","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/med.20149","article-title":"Antiviral drug discovery: ten more compounds, and ten more stories (part B)","volume":"29","author":"De Clercq","year":"2009","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bcp.2011.03.027_bib0125","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/AAC.41.3.594","article-title":"Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation","volume":"41","author":"Xiong","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0130","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1073\/pnas.88.4.1499","article-title":"Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound","volume":"88","author":"Balzarini","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2011.03.027_bib0135","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrmicro975","article-title":"Antivirals and antiviral strategies","volume":"2","author":"De Clercq","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bcp.2011.03.027_bib0140","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0166-3542(92)90084-I","article-title":"Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine","volume":"19","author":"Starrett","year":"1992","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bcp.2011.03.027_bib0145","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1023\/A:1018925723889","article-title":"Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys","volume":"11","author":"Cundy","year":"1994","journal-title":"Pharm Res"},{"key":"10.1016\/j.bcp.2011.03.027_bib0150","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2011.03.027_bib0155","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2011.03.027_bib0160","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1073\/pnas.88.11.4961","article-title":"9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo","volume":"88","author":"Balzarini","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2011.03.027_bib0165","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1128\/AAC.38.9.2180","article-title":"Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture","volume":"38","author":"Heijtink","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/14787210.1.1.21","article-title":"Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections","volume":"1","author":"De Clercq","year":"2003","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"10.1016\/j.bcp.2011.03.027_bib0175","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.270.5239.1197","article-title":"Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine","volume":"270","author":"Tsai","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.bcp.2011.03.027_bib0180","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)-PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0185","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/AAC.42.7.1568","article-title":"Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice","volume":"42","author":"Naesens","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0190","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0195","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1128\/AAC.00460-07","article-title":"Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections","volume":"51","author":"Painter","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.bcp.2011.03.027_bib0200","first-page":"A6","article-title":"Hexadecyloxypropyl tenofovir (CMX157) has enhanced potency in vitro against NRTI-resistant HIV relative to tenofovir and a favourable preclinical profile","volume":"13","author":"Lanier","year":"2008","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.bcp.2011.03.027_bib0205","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1021\/ja043045z","article-title":"Deoxythreosyl phosphonate nucleosides as selective anti-HIV agents","volume":"127","author":"Wu","year":"2005","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bcp.2011.03.027_bib0210","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1021\/jo00008a013","article-title":"Regiospecific and highly stereoselective electrophilic addition to furanoid glycals: synthesis of phosphonate nucleotide analogues with potent activity against HIV","volume":"56","author":"Kim","year":"1991","journal-title":"J Org Chem"},{"key":"10.1016\/j.bcp.2011.03.027_bib0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2009.09.014","article-title":"Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine","volume":"85","author":"Cihlar","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bcp.2011.03.027_bib0220","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1128\/AAC.01215-07","article-title":"Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131","volume":"52","author":"Cihlar","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0225","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1128\/AAC.01209-07","article-title":"Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent","volume":"52","author":"Ray","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0230","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/AAC.01183-08","article-title":"Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation","volume":"53","author":"Cihlar","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0235","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1021\/jm011095y","article-title":"6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity","volume":"45","author":"Hol\u00fd","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2011.03.027_bib0240","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.46.7.2185-2193.2002","article-title":"Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates","volume":"46","author":"Balzarini","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0245","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1021\/jm030932o","article-title":"5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity","volume":"46","author":"Hockov\u00e1","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2011.03.027_bib0250","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1081\/NCN-200059772","article-title":"Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines","volume":"34","author":"De Clercq","year":"2005","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.bcp.2011.03.027_bib0255","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1128\/AAC.00838-07","volume":"51","author":"Duraffour","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0260","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1074\/jbc.M109.096529","article-title":"The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization","volume":"285","author":"Herman","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2011.03.027_bib0265","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1021\/jm061281+","article-title":"Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds","volume":"50","author":"Kre\u010dmerov\u00e1","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2011.03.027_bib0270","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1021\/jm0707166","article-title":"Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity","volume":"50","author":"Kre\u010dmerov\u00e1","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2011.03.027_bib0275","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.bcp.2008.08.009","article-title":"Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine","volume":"76","author":"Naesens","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2011.03.027_bib0280","doi-asserted-by":"crossref","first-page":"6778","DOI":"10.1016\/j.bmc.2008.05.058","article-title":"Study of chemical stability of antivirally active 5-azacytosine acyclic nucleoside phosphonates using NMR spectroscopy","volume":"16","author":"Drac\u00ednsk\u00fd","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bcp.2011.03.027_bib0285","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0006-2952(99)00091-X","article-title":"N6-Cyclopropyl-PMEDAP: a novel derivative of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation-inducing properties","volume":"58","author":"Hatse","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2011.03.027_bib0290","first-page":"195","article-title":"9-(2-Phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine: a novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats","volume":"11","author":"Naesens","year":"1999","journal-title":"Oncol Res"},{"key":"10.1016\/j.bcp.2011.03.027_bib0295","first-page":"2562","article-title":"Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir","volume":"58","author":"Liekens","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2011.03.027_bib0300","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1183>3.0.CO;2-K","article-title":"Potent inhibition of hemangiosarcoma development in mice by cidofovir","volume":"92","author":"Liekens","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bcp.2011.03.027_bib0305","first-page":"5057","article-title":"Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir","volume":"61","author":"Liekens","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2011.03.027_bib0310","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1128\/AAC.00103-09","article-title":"GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions","volume":"53","author":"Wolfgang","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0315","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1158\/1078-0432.CCR-07-2061","article-title":"GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma","volume":"14","author":"Reiser","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2011.03.027_bib0320","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/AAC.01172-07","article-title":"Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand","volume":"52","author":"Magee","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2011.03.027_bib0325","doi-asserted-by":"crossref","first-page":"12520","DOI":"10.1128\/JVI.01528-08","article-title":"Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs","volume":"82","author":"Gammon","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.bcp.2011.03.027_bib0330","doi-asserted-by":"crossref","first-page":"9771","DOI":"10.1128\/JVI.74.20.9771-9775.2000","article-title":"Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2)","volume":"74","author":"Otten","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.bcp.2011.03.027_bib0335","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1086\/322781","article-title":"Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection","volume":"184","author":"Van Rompay","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2011.03.027_bib0340","doi-asserted-by":"crossref","first-page":"10358","DOI":"10.1128\/JVI.01073-09","article-title":"Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine","volume":"83","author":"Parikh","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.bcp.2011.03.027_bib0345","doi-asserted-by":"crossref","first-page":"e9310","DOI":"10.1371\/journal.pone.0009310","article-title":"In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide","volume":"5","author":"Rohan","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2011.03.027_bib0350","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bcp.2011.03.027_bib0355","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1097\/01.aids.0000247128.27505.28","article-title":"The role of tenofovir in the prevention of HIV infections","volume":"20","author":"De Clercq","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2011.03.027_bib0360","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2217\/17584310.3.1.3","article-title":"Antiretroviral prophylaxis for the prevention of HIV infection: future implementation challenges","volume":"3","author":"Karim","year":"2009","journal-title":"HIV Ther"},{"key":"10.1016\/j.bcp.2011.03.027_bib0365","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2011.03.027_bib0370","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1165706","article-title":"The challenge of finding a cure for HIV infection","volume":"323","author":"Richman","year":"2009","journal-title":"Science"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295211002140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295211002140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T05:37:19Z","timestamp":1712381839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295211002140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0006295211002140"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2011.03.027","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}